| Literature DB >> 29151047 |
Romana Haneef1,2,3, Amélie Yavchitz1,3,4, Philippe Ravaud1,2,3,4,5, Gabriel Baron3, Ivan Oransky6, Gary Schwitzer7, Isabelle Boutron1,2,3,4.
Abstract
INTRODUCTION: We aim to compare the interpretation of health news items reported with or without spin. 'Spin' is defined as a misrepresentation of study results, regardless of motive (intentionally or unintentionally) that overemphasises the beneficial effects of the intervention and overstates safety compared with that shown by the results. METHODS AND ANALYSIS: We have planned a series of 16 randomised controlled trials (RCTs) to perform a prospective meta-analysis. We will select a sample of health news items reporting the results of four types of study designs, evaluating the effect of pharmacological treatment and containing the highest amount of spin in the headline and text. News items reporting four types of studies will be included: (1) preclinical studies; (2) phase I/II (non-randomised) trials; (3) RCTs and (4) observational studies. We will rewrite the selected news items and remove the spin. The original news and rewritten news will be appraised by four types of populations: (1) French-speaking patients; (2) French-speaking general public; (3) English-speaking patients and (4) English-speaking general public. Each RCT will explore the interpretation of news items reporting one of the four study designs by each type of population and will include a sample size of 300 participants. The primary outcome will be participants' interpretation of the benefit of treatment after reading the news items: (What do you think is the probability that treatment X would be beneficial to patients? (scale, 0 (very unlikely) to 10 (very likely)).This study will evaluate the impact of spin on the interpretation of health news reporting results of studies by patients and the general public. ETHICS AND DISSEMINATION: This study has obtained ethics approval from the Institutional Review Board of the Institut national de la santé et de la recherche médicale (INSERM) (registration no: IRB00003888). The description of all the steps and the results of this prospective meta-analysis will be available online and will be disseminated as a published article. On the completion of this study, the results will be sent to all participants. PROSPERO REGISTRATION NUMBER: CRD42017058941. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Entities:
Keywords: general public; health news; meta-analysis; patients; randomized controlled trials; spin
Mesh:
Year: 2017 PMID: 29151047 PMCID: PMC5702017 DOI: 10.1136/bmjopen-2017-017425
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Series of 16 RCTs that will be included in the prospective meta-analysis. Each RCT will explore the interpretation of news items reporting four study designs: (1) preclinical studies; (2) phase I/II trials (non-randomised); (3) RCTs and (4) observational studies. Each RCT will target four types of populations: (1) French-speaking patients; (2) French-speaking general public; (3) English-speaking patients and (4) English-speaking general public. RCT, randomised controlled trials.
Guidelines to remove spin
| Spin | Interventions/modifications |
| Spin in headline | Delete the misleading information and report the appropriate information. |
| Spin in text | |
|
| |
|
Misleading reporting of study design | Report the appropriate study design. |
|
Not reporting study population if an animal study | Report animal study subjects. |
|
Selective reporting of outcomes | Report the results for all primary outcomes. |
|
Not reporting adverse events | Report adverse events when higher in one group. |
|
Use of linguistic spin | Delete linguistic spin. |
|
Not reporting study limitations and caution specific to study design | Report the study limitations and cautions. The cautions with standardised text are described in |
|
| |
|
Claiming a beneficial effect of intervention despite statistically non-significant results Claiming an equivalent beneficial effect of intervention despite statistically non-significant results in superiority RCTs | Delete this spin and use the generic wording, such as: |
|
Claiming the treatment is safe despite statistically non-significant results in treatment and comparison groups Claiming safety despite adverse events Claiming a causal effect despite non-randomised study design Claiming a beneficial effect despite small sample size not reported Claiming a beneficial effect despite lack of comparator Focus on P value instead of magnitude of the effect (effect size) | Delete this spin; reword and provide the appropriate information when needed. |
|
| |
|
Animal study results to human application Preliminary study results to clinical application Study outcomes to other outcomes for the disease Study intervention to a different intervention Study participants to a larger or different population | Delete the inappropriate extrapolation. |
|
Inappropriate implication for clinical or daily use | Delete the statement and clearly report the immediate unavailability in clinical practice. |
|
| |
| Delete the spin in the statement. | |
| Report the caution or recommendation by study authors, reported in the relevant article when available. | |
RCT, randomised controlled trial.
Reporting of cautions with standardised wording
| Study design | Standardised text |
| Animal or laboratory study | “The study was based on animals; it is impossible to know whether this treatment will work on humans or not.” |
| Small study | “These results are based on a small study; larger studies are needed to understand whether the treatment works across a large population.” |
| Uncontrolled study/Lack of comparator | “Everyone in this study took drug X. Without investigating patients who did not take that drug, it is impossible to know whether taking drug X accounted for the outcome.” |
| Controlled but not randomised study | “The study participants were not randomized. We do not know whether it was drug X or something else that really accounted for the effect observed.” |
| Important adverse event | “The benefit observed should be weighed against the adverse effects (or other downsides such as inconvenience, cost, etc).” |